Cargando…

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis

BACKGROUND: In the phase 3 CASPIAN study (NCT03043872), first-line durvalumab plus etoposide and cisplatin or carboplatin (EP) significantly improved OS versus EP alone in patients with extensive-stage (ES)-SCLC (HR 0.73 [95% CI 0.59–0.91; p = 0.0047]). Here we report results for a preplanned subgro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hotta, Katsuyuki, Nishio, Makoto, Saito, Haruhiro, Okamoto, Isamu, Nakahara, Yasuharu, Hayashi, Hidetoshi, Hayama, Manabu, Laud, Peter, Jiang, Haiyi, Paz-Ares, Luis, Azuma, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134304/ https://www.ncbi.nlm.nih.gov/pubmed/33826027 http://dx.doi.org/10.1007/s10147-021-01899-8

Ejemplares similares

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
por: Chen, Yuanbin, et al.
Publicado: (2022)

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
por: Paz-Ares, L., et al.
Publicado: (2022)

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
por: Zhang, Longfeng, et al.
Publicado: (2020)

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003)
por: Ishii, Hidenobu, et al.
Publicado: (2022)

First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
por: Li, Lijuan, et al.
Publicado: (2023)

Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors
por: Fujiwara, Yutaka, et al.
Publicado: (2019)

Durvalumab in NSCLC: latest evidence and clinical potential
por: Muñoz-Unceta, Nerea, et al.
Publicado: (2018)

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC
por: Sugawara, Shunichi, et al.
Publicado: (2019)

Biomarkers of Response to Etoposide-Platinum Chemotherapy in Patients with Grade 3 Neuroendocrine Neoplasms
por: Lacombe, Caroline, et al.
Publicado: (2021)

The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis
por: Guan, Yelan, et al.
Publicado: (2023)

Oesophageal Cancer Studies in the Caspian Littoral of Iran: The Caspian Cancer Registry
por: Mahboubi, E., et al.
Publicado: (1973)

Characterization of an Etoposide‐resistant Human K562 Cell Line, K/eto
por: Sugawara, Isamu, et al.
Publicado: (1991)

Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis
por: Hirashima, Tomonori, et al.
Publicado: (2019)

Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing
por: Iwama, Eiji, et al.
Publicado: (2018)

Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)
por: Tachihara, Motoko, et al.
Publicado: (2021)

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
por: van der Burg, M E L, et al.
Publicado: (2002)

Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report
por: Sun, Li, et al.
Publicado: (2020)

Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases
por: Shiraishi, Yoshimasa, et al.
Publicado: (2022)

Subgrouping of Iranian children and adolescents based on cardiometabolic risk factors using latent class analysis: The CASPIAN-V study
por: Abbasi-Ghahramanloo, Abbas, et al.
Publicado: (2020)

Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
por: Nakka, Thejeswar, et al.
Publicado: (2022)

Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study
por: Miyawaki, Eriko, et al.
Publicado: (2022)

Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC
por: Rizvi, Naiyer, et al.
Publicado: (2015)

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer
por: Morgensztern, Daniel, et al.
Publicado: (2019)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer
por: Doki, Yuichiro, et al.
Publicado: (2022)

Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017)

Retinal Vasculitis Secondary to Durvalumab
por: R. Andrade, Antonio, et al.
Publicado: (2020)

Durvalumab-induced Severe Gastritis
por: Otohara, Masaya, et al.
Publicado: (2021)

A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients
por: Byers, Lauren Averett, et al.
Publicado: (2017)

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada
por: Elegbede, Anifat A., et al.
Publicado: (2021)

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
por: Forde, Patrick M., et al.
Publicado: (2021)

Methodological and Statistical Comments on CASPIAN-III Study
por: Kabir, Ali
Publicado: (2013)

Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile.
por: de Jong, R. S., et al.
Publicado: (1997)

Biodistribution of etoposide via intratumoral chemotherapy with etoposide-loaded implants
por: Wu, Chunsheng, et al.
Publicado: (2020)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.
por: Seymour, M. T., et al.
Publicado: (1994)

Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study
por: Huang, Qi, et al.
Publicado: (2020)

Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide‐platinum‐atezolizumab treatment
por: Lim, Jeong Uk, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jls55p1jevl6qfu5bfrqcqnn0p